1、Overcoming the In Vitro Prediction Gap | Precision Screening Based on Human Cell Lines Accelerates Drug Efficacy Validation

Traditional 2D cell models fail to simulate the human microenvironment, leading to a disconnect between preclinical data and clinical outcomes. Jennio Bio provides a customized in vitro drug efficacy platform based on standardized human cell lines, which significantly improves the accuracy of drug response prediction and shortens the R&D cycle by more than 30%.

2、Service Overview

In drug R&D, in vitro human cell line models serve as the first gate for evaluating the efficacy of candidate compounds. However, the industry is generally faced with two major challenges:

1. Model Limitations: Commercial cell lines have a single genetic background and cannot reflect patient heterogeneity, resulting in misjudgment of drug efficacy.
2. Low Data Conversion Rate: Only 20% of in vitro positive results can be reproduced in in vivo validation, increasing R&D costs and failure risks.

Jennio Bio builds a highly predictive in vitro drug efficacy model through a clinical-grade human cell bank and functional verification platform, supporting pharmaceutical companies accurately identify candidate drugs and reduce the elimination rate in Phase I clinical trials.

3、Our Services

End-to-end solutions tailored to application scenarios across drug development stages:

1. Early Screening: High-Throughput Activity Evaluation

• Targeted Drug Sensitivity Analysis
  • Covering more than 15 cancer types such as lung cancer, liver cancer, and breast cancer (e.g., HCC1937, Hep3B)
  • Detection indicators: WB target detection, IC50 value calculation, proliferation inhibition rate (MTT/CTG), apoptosis induction (Annexin V/PI)
• Drug Resistance Mechanism Research
  • Customized construction of EGFR-TKI-resistant cell lines (e.g., PC-9/ER), combined with CRISPR technology to verify target pathways

2. Mechanism Verification: Functional Phenotypic Analysis
   • Migration/invasion ability: Transwell® for quantitative assessment of tumor metastasis potential (Matrigel matrix simulates the microenvironment)
   • Angiogenesis evaluation: Endothelial cell tube formation assay (HUVEC model)
   • Immunomodulatory effect: Co-culture system (tumor cells + PBMC) to detect the impact of PD-1/CTLA-4 antibodies on T cell activation

3. Primary Cell Transformation Research

Patient-Derived Tumor Cells (PDTC)

• Isolated and cultured from surgical samples, retaining the original tumor characteristics (STR identification)
• Supporting personalized drug sensitivity testing (e.g., anti-tumor drug response profile of colorectal cancer)

4、Technology Platforms and Advantages

Cell Resource Bank

• More than 1,000 human-derived cell lines (from ATCC/DSMZ, including over 300 fluorescent tracer lines)
• Chinese primary tumor cell bank: 38 liver cancer strains, 42 colorectal cancer strains, etc., covering high-frequency mutations in the Asian population

Innovative Technology Platforms

• CRISPR-Cas9 gene editing: Construction of KO/overexpression tool cells
• 3D spheroid culture: Simulating the tumor microenvironment

Differentiated Advantages

• The only integrated PDX-derived cells: In vivoand in vitro data linkage (e.g., PDX model drug efficacy → in vitro drug resistance mechanism tracing)
• Automated high-throughput screening: 96-well plate compatible, processing more than 1,000 samples per day

5、Service Process

1. Demand consultation: Response within 24 hours, customized experimental protocols (target/cell line/detection matrix)

2.Model Construction

• STR identification of cell lines → QC release (mycoplasma/virus detection)
• Gene editing verification (Sanger sequencing + WB)

3.Experiment Execution

• Real-time data sharing
• Recording of key milestones

4. Deliverables

• GLP-aligned standard reports (including raw data + statistical analysis)
• Scalable to in vivovalidation (seamless connection with CDX/PDX models)

6、Quality Control and Compliance

International Standard Certifications

• ISO 9001:2015 Quality Management System
• BSL-2 Laboratory Safety Certification (CDC/NIH standards)

Data Integrity Assurance

• Double-blind review mechanism (cross-validation by third-party institutions)
• Electronic Lab Notebook (ELN) for full traceability

7、Case Studies

Case 1: In Vitro Screening of Lung Cancer Targeted Drugs

Requirement: Screen EGFR-T790M mutation-sensitive drugs in 10 lung cancer cell lines

Solutions:

• WB confirmation of target expression
• High-throughput CTG detection (8 concentration gradients, n=3)

Results:

• Rapid in vitro screening of highly sensitive compounds
• Consistency of in vivo validation > 90% (H1975 CDX model)

Lung Cancer Cell Drug Sensitivity Heatmap

View the complete case report >

8、Benefits of Partnership

• Custom Flexibility:On-demand combination of cell lines/detection panels (e.g., “comprehensive screening of 81 lung cancer strains” or “in-depth mechanism verification of a single target”).
• Efficiency Improvement: Standardized processes shorten the cycle: cell delivery ≤ 15 days, drug efficacy report ≤ 15 days (30% faster than the industry average).
• Cost Control:Shared database avoids repetitive experiments (e.g., direct access to pre-validated data for HER2+ breast cancer).
• Risk Aversion:Design of preclinical-clinical translation pathways (in vitro → PDX → toxicology → IND application support).

9、FAQ

Q1: Is the construction of rare mutant cell lines supported?

A: Yes! We have successfully constructed the FGFR2-fused cholangiocarcinoma cell line (ICC-1) and provide one-stop services for mutation verification and drug sensitivity analysis.

Q2: Can the data be used for FDA/EMA applications?

A: We support GLP-aligned standard reports that comply with the ICH S9 guidelines. We have helped 3 anti-cancer drug IND applications obtain approval.

10、Laboratory Highlights

Automated High-Throughput Screening Platform

Core Facilities:

• Hamilton STAR Automated Liquid Handling System (error < 1%)
• High-content imaging analyzer (ImageXpress Micro, 40X dynamic tracking)

View More

11、Contact Us

Consult Experts: 3691125803@qq.com | +86 18802035152